Literature DB >> 19895902

Tuberculin immunotherapy: its history and lessons to be learned.

Cristina Vilaplana1, Pere-Joan Cardona.   

Abstract

The use of tuberculin for the therapy of tuberculosis was attempted more than 100 years ago and abandoned because of its adverse reactions. In this historical review we point out that some of the intensive efforts to avoid the reactions were based on the best scientific rationale available at that time. Balancing the dosage and intervals of tuberculin delivery with clinical and laboratory monitoring of patients achieved a limited success, with implications, toward current research in the field. The role of economical and social aspects at that time is also a lesson to be learned toward current approaches to tuberculosis control. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895902     DOI: 10.1016/j.micinf.2009.10.006

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  4 in total

Review 1.  A spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis.

Authors:  Pere-Joan Cardona
Journal:  Clin Dev Immunol       Date:  2011-03-13

Review 2.  The Progress of Therapeutic Vaccination with Regard to Tuberculosis.

Authors:  Pere-Joan Cardona
Journal:  Front Microbiol       Date:  2016-09-28       Impact factor: 5.640

3.  RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice.

Authors:  Satria A Prabowo; Hannah Painter; Andrea Zelmer; Steven G Smith; Karin Seifert; Merce Amat; Pere-Joan Cardona; Helen A Fletcher
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

4.  Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice.

Authors:  Monalisa Martins Trentini; Alex Issamu Kanno; Dunia Rodriguez; Lazaro Moreira Marques-Neto; Silas Fernandes Eto; Ana Marisa Chudzinki-Tavassi; Luciana Cezar de Cerqueira Leite
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.